A compound called AP503 has been shown to strengthen bones in mice by activating GPR133, a receptor involved in GPR133 bone formation, in a study led by scientists from Leipzig University and, according to ScienceAlert, Shandong University in China.
The findings, published in Signal Transduction and Targeted Therapy, are described as experimental. AP503 has not been tested in humans, and the researchers are clear that considerable further work is needed before any clinical application could be considered.
What the GPR133 bone formation research actually found
GPR133 belongs to a class called adhesion G protein-coupled receptors. These receptors sit on cell surfaces and respond to signals from their surrounding environment. The Leipzig-Shandong team found that when GPR133 is impaired by genetic changes, mice show signs of bone density loss at an early age, in a pattern the researchers describe as similar to osteoporosis in humans.
AP503 was identified through a computer-assisted screen as a stimulator of GPR133. When the researchers used it to activate the receptor, they found it increased bone strength in both healthy mice and in mice with osteoporosis-like bone loss. The mechanism, as the team describes it, involves shifting the balance between two cell types: osteoblasts, which build new bone tissue, and osteoclasts, which break down old bone. Activating GPR133 appears to encourage osteoblast activity while reducing osteoclast activity, pushing the balance toward stronger bone.
‘If this receptor is impaired by genetic changes, mice show signs of loss of bone density at an early age, similar to osteoporosis in humans. Using the substance AP503, which was only recently identified via a computer-assisted screen as a stimulator of GPR133, we were able to significantly increase bone strength in both healthy and osteoporotic mice,’ said Professor Ines Liebscher, lead investigator of the study from the Rudolf Schönheimer Institute of Biochemistry at the Faculty of Medicine.
AP503 appears to imitate the natural process that activates GPR133. The researchers suggest one potential application could be osteoporosis associated with menopause, when declining hormone levels can accelerate bone loss. That remains speculative at this stage.
A parallel effect on muscle, and a decade of receptor research
The study adds to an earlier finding from the Leipzig group that activation of GPR133 with AP503 also strengthens skeletal muscle. The bone results now extend that picture. ‘The newly demonstrated parallel strengthening of bone once again highlights the great potential this receptor holds for medical applications in an aging population,’ said Dr. Juliane Lehmann, lead author of the study and a researcher at the Rudolf Schönheimer Institute of Biochemistry.
Whether a compound capable of acting on both bone and muscle simultaneously would behave safely in humans is an open question. The dual effect is, at minimum, a reasonable prompt for further investigation, given that older adults often experience decline in both tissues concurrently.
The international dimension of the collaboration matters for context. Leipzig University has maintained adhesion G protein-coupled receptors as a core research priority through Collaborative Research Center 1423, which focuses on how these receptors change shape, become activated, and transmit signals inside cells. That programme has been running for more than a decade. The involvement of Shandong University, as reported by ScienceAlert, adds a cross-institutional element to what the report presents primarily as a Leipzig initiative.
Osteoporosis is not a niche problem. In Germany alone, the report states, about six million people are affected, most of them women. Existing therapies carry limitations and side effects, which is the stated motivation for seeking new biological targets. GPR133 is one such candidate, though the distance from a mouse model to a safe, effective human treatment is substantial and should not be glossed over.
The Leipzig team says it is now pursuing follow-up projects aimed at understanding GPR133 more fully, and is investigating whether AP503 could have applications in other diseases. The receptor’s wider functions throughout the body remain under examination, with GPR133 bone formation representing one confirmed area of activity in the mouse studies published so far.
